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lObjective: To estimate the cost-effectiveness of once-daily tenofovir/
emtricitabine compared with twice-daily zidovudine/lamivudine and
once-daily abacavir/lamivudine in treatment-naïve adults with HIV-1
infection in the United States. Methods: A Markov model with four
therapy lines and six health states based on CD4 cell-count ranges
was developed to estimate lifetime costs and health outcomes. Efficacy
data (virologic response and CD4 cell-count changes) for first-line
herapy were from 144-week results of Study 934 comparing tenofovir/
mtricitabine with zidovudine/lamivudine and 48-week results of
tudy CNA30024 comparing abacavir/lamivudine with zidovudine/
amivudine, all in combination with efavirenz. Data from Study
NA30024 for abacavir/lamivudine were adjusted to allow for an indi-
ect comparison with tenofovir/emtricitabine. Subsequent therapy
ines were based on likely baskets of antiretroviral therapy recom-
ended by US treatment guidelines. Utility values, mortality rates, and
osts (2009 US dollars) were obtained from published sources. Base-
ase results were tested in sensitivity and variability analyses.
esults: Average discounted results showed that individuals using
enofovir/emtricitabine were predicted to remain on first-line therapy
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doi:10.1016/j.jval.2011.01.009or 7.7 years, accrue lifetime costs of $747,327, and experience 15.75
uality-adjusted life-years (QALYs), compared with 6.0 years, $777,090,
nd 15.68 QALYs for individuals using abacavir/lamivudine and 5.8
ears, $778,287, and 15.44 QALYs for individuals using zidovudine/
amivudine. Tenofovir/emtricitabine was cost-effective compared with
the other two first-line regimens in more than 75% of all probabilistic sensi-
tivity analysis simulation runs for every willingness-to-pay threshold be-
tween $0 and $250,000 per QALY gained. Results were robust in variability
and one-way sensitivity analyses. Conclusions: Tenofovir/emtricitabine
was predicted to be more effective and cost-saving compared with aba-
cavir/lamivudine and zidovudine/lamivudine in treatment-naïve
adults with HIV-1 infection in the United States. © 2011, International
Society for Pharmacoeconomics and Outcomes Research (ISPOR). All
rights reserved.
Keywords: AIDS, cost-effectiveness analysis, drug combinations,
Markov model.
Copyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Major therapeutic advances in the 15 years since the introduction of
highly active antiretroviral therapy (HAART) have led to a reduction
in morbidity and mortality specifically due to acquired immune de-
ficiency syndrome (AIDS) [1–5] and an increase in life expectancy
(37.3 years postinfection) for individuals with human immunodefi-
ciency virus (HIV) infection [6]. Rising antiretroviral drug costs and
longer life expectancies have led to higher lifetime treatment costs,
increasing from $94,000 in 1992 [7] to over $600,000 in 2004 [8]. There-
ore, costs of antiretroviral regimens have become important consid-
rations in addition to efficacy and safety.
First-line therapy plays a significant role in each individual’s
ong-term health outcomes and total health care costs. Durable
uppression of plasma HIV ribonucleic acid (RNA) inhibits disease
rogression and reduces disease-related morbidity and mortality
9]. First-line therapy currently represents each individual’s best
hance at durable viral suppression because resistance is low and
dherence to relatively tolerable and simple regimens (i.e., regi-
* Address correspondence to: Anita J. Brogan, RTI Health Solutio
27709 USA.
E-mail: abrogan@rti.org.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.ens with low pill burden and daily dosing) is likely to be high
10–12]. The choice of initial therapy is important because short-
erm outcomes (i.e., viral suppression, side effects, and develop-
ent of resistance) may affect an individual’s duration on first-
ine therapy [13] and thus progression through subsequent lines of
herapy. Delaying more complex and expensive therapy regimens
epresents an additional benefit potentially conferred by longer
rst-line treatment durations.
For treatment-naïve individuals with HIV-1 infection, United
tates (US) treatment guidelines recommend using the nucleotide/
ucleoside reverse transcriptase inhibitor (NRTI) fixed-dose combi-
ation tenofovir DF/emtricitabine (TDF/FTC) with the non-nucleo-
ide reverse transcriptase inhibitor (NNRTI) efavirenz (EFV), one of
wo protease inhibitors (PI) boosted with low-dose ritonavir (/r), or
he integrase strand transfer inhibitor raltegravir [9]. The fixed-dose
ombinations abacavir/lamivudine (ABC/3TC) and zidovudine/lami-
udine (ZDV/3TC) are listed as alternative NRTI pairs.
Studies testing EFV-based regimens in treatment-naïve indi-
iduals have shown that more individuals receiving TDF/FTC ex-
.O. Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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658 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 7 – 6 6 4perienced virologic response than individuals receiving other
NRTI pairs [14], including ZDV/3TC [15–17] and ABC/3TC [18–21].
dditionally, a recent meta-analysis found that TDF/FTC was
ore effective than ABC/3TC when used with a boosted PI as a
rst-line regimen [22]. For treatment-naïve individuals overall,
NRTI-based regimens have been associated with better efficacy
13,23–26] and longer average treatment duration [13,27] than PI-
ased regimens.
This study evaluates the cost-effectiveness of once-daily TDF/
TC compared with twice-daily ZDV/3TC and once-daily ABC/3TC,
ach used in combination with EFV in treatment-naïve adults with
IV-1 infection in the US, to highlight the potential effects of the
hoice of first-line NRTI pair on long-term costs and health out-
omes.
Methods
Model overview
A Markov model with a 1-year cycle period was developed in Microsoft
Excel (Microsoft Corporation, Redmond, WA) to follow a population of
treatment-naïve HIV-positive individuals as they progressed through
rst-line, second-line, third-line, and non-suppressive therapy
Fig. 1). Costs and health outcomes were calculated for each of three
rst-line HAART regimens being compared: TDF/FTC, ABC/3TC, and
Fig. 1 – Markov model with health states based on CD4+ cell
ount. *Individuals on first-line therapy can transition to any
D4+ cell-count health state (not just the adjacent health
states) in a given year and are at risk for adverse events
including anemia, lipodystrophy, and myocardial infarction.
Individuals in the ABC/3TC arm incur one-time costs for
HLA-B*5701 screening, and individuals in the TDF/FTC arm
incur annual costs for renal monitoring. †Individuals on
second- and third-line therapies can remain in their current
health state or transition upward in a given year. The model
makes this assumption because estimates of person-level
variation around mean CD4+ cell-count increases were not
vailable from published sources and because, in clinical
ractice, individuals would typically switch to a new therapy
egimen upon virologic failure (i.e., before CD4+ cell-count
ecline begins). ‡Individuals may transition to death from
ny health state. For deaths related to AIDS, transition
robabilities vary by CD4+ cell count; for deaths unrelated to
IDS, transition probabilities vary by age and gender and
ncrease over time to reflect aging of the cohort. 3TC,
amivudine; ABC, abacavir; FTC, emtricitabine; TDF, tenofovir
F. Arrows indicate annual transitions.ZDV/3TC, each used in combination with EFV (referred to hereafter
by NRTI pair).
Using clinical trial data at various time points, the model
tracked the percentage of individuals in each arm who remained
on first-line therapy and who had HIV-1 RNA less than 400 copies/
mL. Those individuals who dropped out of this group for any rea-
son, including adverse events, lack of initial virologic response, or
loss of initial virologic response, switched from first-line to sec-
ond-line therapy. A threshold viral load of 400 copies/mL was cho-
sen as a clinically relevant point above which individuals would
likely switch to a new regimen.
Individuals entered the model in one of six possible Markov-
model health states defined by CD4 cell-count ranges ( 500,
51–500, 201–350, 101–200, 51–100, and 0–50 cells/L). Every year,
individuals remained in their current health state or moved to
another state of the model, where transition probabilities were
estimated from clinical trial and observational cohort data. There
was a chance of death from any therapy line, HIV-1 RNA level, or
CD4 cell-count range.
The model was developed to focus on different first-line regimens
rom the NRTI drug class when combined with EFV. First-line thera-
ies were modeled using clinical trial data. As individuals switched
o later lines of therapy, costs and efficacy were based on a basket of
egimens recommended by the US treatment guidelines [9].
The analysis took a US societal perspective. Incremental cost-
ffectiveness ratios included direct medical costs in the numera-
or and either life-years or quality-adjusted life years (QALYs) in
he denominator. As recommended for health economic analyses,
ndirect costs, including those associated with productivity losses,
ere assumed to be captured in the QALY estimates [28].
Input parameters
Population characteristics and efficacy data for first-line
regimens
A MEDLINE search and a review of scientific conference abstracts
for clinical trials comparing the model’s first-line regimens head-
to-head identified four studies: Study 934 [15–17], Study CNA30024
[29], the ACTG 5202 study [18–19], and the ASSERT study [20–21].
one of these studies included all three first-line regimens. Study
34 and Study CNA30024 had comparable virologic efficacy end-
oints (time to regimen failure) for all three first-line regimens,
llowing for an indirect comparison of TDF/FTC and ABC/3TC. The
CTG 5202 study was excluded because full results with compa-
able endpoints have not been published; the ASSERT study was
xcluded because the unusually high drop-out rate confounded
he efficacy results.
Characteristics of the modeled population, including baseline
ender (86.5% male), mean age (38 years), and CD4 cell-count
istribution (Appendix S1 found at doi:10.1016/j.jval.2011.01.009),
ere assumed to be equivalent to those of the modified intent-to-
reat population in Study 934, a head-to-head clinical trial comparing
DF/FTC and ZDV/3TC each in combination with EFV in treatment-
aïve HIV-1–infected individuals [15–17]. Baseline characteristics
vailable from study CNA30024, which compared ABC with ZDV each
sed in combination with 3TC and EFV, were similar.
Clinical efficacy and safety data for the TDF/FTC plus EFV arm
nd the ZDV/3TC plus EFV arm of the model were derived from the
44-week results of Study 934 [15–17]. Efficacy and safety data for
he ABC/3TC plus EFV arm of the model were estimated from the
8-week results of Study CNA30024 [29]. These two trials both in-
luded ZDV/3TC plus EFV, which allowed for a direct comparison
etween TDF/FTC and ZDV/3TC and an indirect comparison between
DF/FTC and ABC/3TC. To make the indirect comparison, efficacy
arameters (virologic response and CD4 cell-count changes) for
ABC/3TC were estimated by applying the relative difference between
the ABC/3TC arm and the ZDV/3TC arm of Study CNA30024 to the
f
S
ZDV
659V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 7 – 6 6 4ZDV/3TC arm of Study 934. This technique maintained the same
relative difference between ABC/3TC and ZDV/3TC in the model as
was observed in Study CNA30024, allowing for a balanced compari-
son between the three first-line HAART regimens.
The proportion of clinical trial participants remaining on first-
line therapy with HIV-1 RNA less than 400 copies/mL at various
time points was used to determine the proportion of individuals
remaining on first-line therapy during each of the first 3 years of
the model. Beyond year 3, the model extrapolated data from base-
line through week 144, using an exponential function to estimate
an annual probability of switching from first line (Table 1).
Immunologic response, measured by annual increase in CD4
cell count, was used to estimate the transition probabilities be-
tween the CD4 cell-count health states of the model. Specifically,
transition probabilities were calculated from the means and stan-
dard deviations of the CD4 cell-count increases observed at 48,
96, and 144 weeks in Study 934 and from the mean increase ob-
Table 1 – Clinical efficacy for individuals on first-line thera
Model input TDF/FTC  E
Virologic response (HIV-1 RNA  400 copies/mL)
through year 3
24 weeks 89.8%
48 weeks 84.4%
96 weeks 73.7%
144 weeks 70.9%
Modeled virologic response after year 3
Annual probability of switching therapy line 0.09
Immunologic response
Mean (SD) CD4 cell-count increase from
baseline to 48 weeks (cells/L)
190 (11
Mean (SD) CD4 cell-count increase from
baseline to 96 weeks (cells/L)
270 (14
Mean (SD) CD4 cell-count increase from
baseline to 144 weeks (cells/L)
312 (16
Long-term (after year 3) mean annual CD4
cell-count increase (cells/L)
21
3TC, lamivudine; ABC, abacavir; EFV, efavirenz; FTC, emtricitabine; H
deviation; TDF, tenofovir DF; ZDV, zidovudine.
* All efficacy data for ABC/3TC  EFV were estimated by multiplying
the ABC/3TC  EFV and the ZDV/3TC  EFV arms of Study CNA300
† Virologic response at 48 weeks in Study CNA30024: ZDV/3TC  EFV
‡ Median CD4 cell-count increases at 48 weeks in Study CNA30024:
Table 2 – Summary of regimens used, cost, and clinical effi
therapy line.
Second line
HAART regimen [9] Lopinavir/r (40%) or atazan
(60%)  2 NRTIs*
Annual cost (2009 USD) [9,34] $21,933
Median time on therapy (years) [27] 4.3
Annual probability of switching 0.149
Annual change in CD4 cell count
[30–33]
46.90 cells/L
HAART, highly active antiretroviral therapy; HIV-1, human immunod
transcriptase inhibitor; /r, boosted with low-dose ritonavir; USD, US
* NRTIs used in each therapy line are assumed to be in the following m
abacavir/lamivudine.
† For third-line therapy, the average was estimated using the CD4 c
CD4 cell-count increase observed between 24 and 48 weeks (9 cellthen was divided by the median time on therapy [27].served at 48 weeks in Study CNA30024. After week 144 (year 3), the
model allowed for a modest continued increase in CD4 cell count
or those individuals still on first-line therapy (Table 1) (Appendix
2 found at doi:10.1016/j.jval.2011.01.009).
Efficacy data for post–first-line regimens
In subsequent therapy lines, individuals received treatment accord-
ing to US treatment guidelines [9] and current clinical practice. Indi-
viduals received a PI-based regimen as second-line therapy and
raltegravir, etravirine, darunavir/r, and two NRTIs as third-line ther-
apy. For non-suppressive therapy, the model assumed individuals
would remain on a drug regimen equal in cost to their third-line
regimen, despite the initiation of treatment failure. While on each
post–first-line regimen in the model, individuals experienced an av-
erage annual change in CD4 cell count based on studies of HIV-
infected individuals at different stages of disease (Table 2) [30–33].
5-17] ZDV/3TC  EFV [15-17] ABC/3TC  EFV [29]*
79.8% 83.2%
72.4%† 75.5%†
61.9% 64.5%
58.1% 60.5%
0.1135 0.1135
158‡ (107.3) 213‡ (144.7)
237 (136.4) 320 (183.9)
271 (147.4) 365 (198.8)
17 22.9
human immunodeficiency virus; RNA, ribonucleic acid; SD, standard
tudy 934 data for ZDV/3TC  EFV by the relative difference between
%; ABC/3TC  EFV  74% [29].
/3TC  EFV  155 cells/L; ABC/3TC  EFV  209 cells/L [29].
for HIV-1–infected individuals receiving HAART, by
Third line Non-suppressive
Raltegravir  etravirine 
darunavir/r  2 NRTIs*
Raltegravir  etravirine 
darunavir/r  2 NRTIs*
$46,034 $46,034
4.2 N/A
0.152 0.000
41.00 cells/L† –22.00 cells/L
ency virus; N/A, not applicable; NRTI, nucleotide/nucleoside reverse
s.
0% tenofovir DF/emtricitabine, 20% zidovudine/lamivudine, and 20%
unt increase from baseline to 48 weeks (108 cells) and assuming the
tinued for the remaining time on therapy [31–32]. The total increasepy.
FV [1
13
1.7)
7.5)
1.2)
IV-1,
the S
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660 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 7 – 6 6 4In each year of the model, a certain percentage of individuals in
each therapy line switched to the next therapy line. The annual
probabilities of switching were calculated from the median time
on each therapy line as observed in a recent United Kingdom co-
hort study by Beck and colleagues [27]. Individuals on non-sup-
pressive therapy were assumed to remain on non-suppressive
therapy until death (Table 2).
Cost data
First-line annual antiretroviral drug costs for TDF/FTC, ABC/3TC,
and ZDV/3TC, each in combination with EFV, were $16,819,
$16,391, and $15,621, respectively. For each subsequent therapy
line, average annual antiretroviral drug costs were estimated
based on the HAART regimens used (Table 2). Drug costs were
taken from the wholesale acquisition cost from the Red Book [34]
for the indicated daily dose for each antiretroviral drug.
Individuals in each CD4 cell-count range in the model in-
urred costs while in that health state. Annual non-antiretrovi-
al medical and medication costs by CD4 cell-count range were
erived from a US study by Gebo and colleagues [35], which
stimated inpatient, outpatient, and emergency department
tilization and costs through interviews with HIV-infected par-
icipants (Table 3).
Lastly, resource use (additional laboratory tests, a resistance
ssay, and a clinician visit) for switching therapy line was based on
linical expert opinion, and the cost ($829 per switch) [36] was
ssumed the same for each switch.
All costs were inflated to 2009 US dollars, when necessary, us-
ng the medical care component of the consumer price index [37].
Utility and mortality data
In each CD4 cell-count range, individuals were assumed to expe-
rience different levels of quality of life, quantified by different util-
ity weights. Utility weights taken from community-based prefer-
ences [38] were mapped to the model health states as follows:
AIDS (CD4 range 0–50), symptomatic HIV-1 infection (CD4 range
0–350), and asymptomatic HIV-1 infection (CD4 range  350)
(Table 3).
Mortality was modeled using an annual probability of death
due to causes related or unrelated to AIDS. For AIDS-related
causes, the model used mortality rates by CD4 cell-count range
1] and converted these rates to probabilities (Table 3). The proba-
ility of death from non–AIDS-related causes was based, in part,
n age- and gender-specific 2006 US general population mortality
ata [39], weighted by the percentage of males and females in the
odeled population. Individuals entered the model at age 38; an
nnual adjustment factor, estimated by fitting an exponential
urve to age-specific mortality data, was applied to account for
ging. A relative risk value of 2.5 [40] was applied to the general
Table 3 – Annual non-ARV medical and medication costs,
range.
CD4 cell-count range Medical costs
(2009 USD) [35]*
Non-AR
(2009
0–50 $41,469
51–100 $19,505
101–200 $19,505
201–350 $14,037
351–500 $14,037
 500 $9473
AIDS, acquired immune deficiency syndrome; ARV, antiretroviral; US
* Costs were inflated to 2009 USD using the medical care component
† Annual rates were converted to annual probabilities using the equopulation mortality data, to account for higher non–AIDS-elated mortality rates observed among individuals with HIV-1
han in the general population. This relative-risk value does not
nclude AIDS-related deaths but captures other causes of ele-
ated death rates among individuals with HIV, such as drug
verdose, hepatitis co-infection, or cardiovascular disease [4 –
], which is now known to be associated with HIV-1 itself and
ome antiretroviral therapies.
Adverse events
Adverse events (anemia, lipoatrophy, myocardial infarction) that im-
pact significantly different proportions of individuals between arms
of the model were modeled explicitly to capture the (differential)
effects on costs, quality of life, and adherence. In addition, the model
included the one-time cost for the HLA-B*5701 screening test for in-
dividuals in the ABC/3TC arm of the model and annual renal moni-
toring costs for individuals in the TDF/FTC arm of the model [41-45]
(Table 4).
Model outcomes
The model estimated total direct medical costs, including antiret-
roviral drugs costs, costs for adverse events, other medical costs
(including costs for disease monitoring, switching therapy lines,
treating opportunistic and other infections and adverse events
other than those explicitly modeled), and non-antiretroviral drug
costs. Health outcomes included life-years, QALYs, years on first-
line therapy, percentages of deaths due to AIDS-related causes,
and percentages of people remaining on first-line therapy (for time
horizons shorter than remaining lifetime only). Incremental cost-
effectiveness ratios included the incremental cost per life-year
gained and per QALY gained. As recommended for US cost-effec-
tiveness analyses, all costs and outcomes were discounted at a 3%
annual rate [28].
Uncertainty and variability analyses
In addition to the base-case analysis, extensive analyses were per-
formed to evaluate the impact of parameter uncertainty on the
model results. One-way sensitivity analysis was performed using
realistic ranges for each parameter derived from published
sources to the extent possible (Appendix S1). Probabilistic sensi-
tivity analysis was performed by simultaneously sampling all in-
put parameters from appropriate probability distributions in
10,000 Monte Carlo simulations (Appendix S1). In addition, vari-
ability analysis was conducted to test the impact of modeling as-
sumptions, including the model time horizon, discount rate, and
y values, and AIDS-related mortality, by CD4+ cell-count
ug costs
) [35]*
Utility values
[38]
Annual probability of
AIDS-related death [1]†
0.778 0.162
0.841 0.054
0.841 0.022
0.841 0.008
0.937 0.004
0.937 0.004
dollars.
e US consumer price index [37].
1  erate.utilit
V dr
USD
$9957
$6540
$6540
$4173
$4173
$3397
D, US
of thincidence and cost of adverse events.
bserv
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Base-case results
The model estimated that TDF/FTC had the lowest discounted
lifetime costs ($747,327) compared with either ABC/3TC ($777,090)
or ZDV/3TC ($778,287) (Table 5). Antiretroviral drugs represented
approximately 65% of lifetime costs for all arms. The model esti-
mated that TDF/FTC resulted in more life-years and QALYs com-
pared with either ABC/3TC or ZDV/3TC. Therefore, TDF/FTC was
the dominant first-line treatment option, exhibiting lower costs
and more QALYs compared with both ABC/3TC and ZDV/3TC.
Uncertainty analysis results
One-way sensitivity analysis demonstrated that the model results
were most sensitive to efficacy parameters for the first-line regi-
mens (virologic response, CD4 cell-count increases), annual
change in CD4 cell count in later therapy lines, and antiretroviral
drug costs in later therapy lines. For the pair-wise comparison
between TDF/FTC and ZDV/3TC, TDF/FTC remained the dominant
treatment strategy (i.e., exhibited lower costs and better health
outcomes) for all ranges tested in the one-way sensitivity analysis.
TDF/FTC remained dominant compared with ABC/3TC for all
ranges tested, with the exception of instances in which the sensi-
tivity analysis examined CD4 cell-count increases that were
higher for ABC/3TC than for TDF/FTC. In these cases, ABC/3TC
exhibited higher costs and more QALYs than TDF/FTC, but the
incremental cost-effectiveness ratio of ABC/3TC versus TDF/FTC
remained above $96,000 per QALY gained.
Probabilistic sensitivity analysis revealed that TDF/FTC was
cost-effective compared with ABC/3TC and ZDV/3TC in more than
75% of all simulation runs for every willingness-to-pay threshold
between $0 and $250,000 per QALY gained (Fig. 2). Specifically, at a
willingness to pay of $50,000 per QALY gained, TDF/FTC was pre-
dicted to be cost-effective 88.1% of the time, compared with 7.8%
for ABC/3TC and 4.1% for ZDV/3TC.
Variability analysis results
Short-term model results found that, compared with the other two
first-line regimens, a larger percentage of individuals remained on
TDF/FTC at 5 years (19%–23% more). Undiscounted lifetime results
revealed that individuals initiating therapy with TDF/FTC re-
Table 4 – Incidence, costs, and utility decrements for adver
Adverse event TDF/FT
Anemia
Incidence in year 1 [15,29] 0
One-time treatment cost [41] $
Lipoatrophy
Two-year incidence [24] 11
Annual utility decrement during first line [42] 0
Myocardial infarction
Annual incidence during first line [43] 0
Treatment cost in first year [44] $1
Treatment cost in subsequent years [44] $
Annual utility decrement during remaining
lifetime [45]
0
HLA-B*5701 one-time screening cost [36]
Annual cost for renal monitoring during first-
line therapy [36]
3TC, lamivudine; ABC, abacavir; EFV, efavirenz; FTC, emtricitabine; T
* Percentage of individuals developing anemia at 48 weeks in the ZD
† Incidence of lipoatrophy for ABC/3TC was assumed equal to that omained on first-line therapy 2.4 and 2.7 years longer than individ-uals initiating therapy with ABC/3TC or ZDV/3TC, respectively.
The incremental results of the model were consistent for different
time horizons and discount rates, with TDF/FTC being the domi-
nant first-line treatment strategy in most cases. Conclusions of
the model also did not change when myocardial infarction rates
were set equal to zero for all arms (Table 5). Additional scenarios
testing a rate of 5% for hypersensitivity reaction instead of HLA-
B*5701 screening for the ABC/3TC arm or a rate of 2% for renal
toxicity for the TDF/FTC arm showed that TDF/FTC remained the
dominant treatment strategy (results not shown).
Discussion
This analysis demonstrates that initiating HAART with TDF/FTC
plus EFV (the components of Atripla) resulted in lower lifetime
costs and more years on first-line therapy, life-years, and QALYs,
compared with either ABC/3TC plus EFV or ZDV/3TC plus EFV as a
first-line regimen in treatment-naïve adults with HIV-1 infection.
Model results were driven by better virologic response in the TDF/
FTC arm, which allowed more individuals to delay higher-cost,
later-line therapy and eventual disease progression.
In general, sensitivity analysis found that the results of the
model were robust. Probabilistic sensitivity analysis showed that
TDF/FTC was cost-effective, compared with ABC/3TC and ZDV/
3TC, the large majority of the time ( 75%) over a wide range of
willingness-to-pay thresholds. The model was sensitive to the
clinical data (particularly for the comparison between TDF/FTC
and ABC/3TC), indicating the importance of including head-to-
head data for these two regimens. Nevertheless, the cost-effec-
tiveness results supported the US clinical treatment guidelines,
which recommend TDF/FTC as the preferred NRTI pair for treat-
ment-naïve individuals [9].
To our knowledge, there is only one other US study comparing
NNRTI-based regimens in treatment-naïve individuals: Schack-
man and colleagues [46] found that initiating HAART with ABC/
3TC and the HLA-B*5701 screening test was cost-effective if ABC/
3TC had efficacy equal to TDF/FTC. Our study, which attempted to
model the difference in efficacy between ABC/3TC and TDF/FTC
via an indirect comparison using data from two head-to-head clin-
ical trials, found that TDF/FTC dominated ABC/3TC in the base-
case analysis. However, the results of both our model and the
vents during first-line therapy.
EFV ABC/3TC  EFV ZDV/3TC  EFV
2.16% 5.12%*
$5349 $5349
11.94%† 39.68%
0.10 0.10
0.54% 0.32%
$16,978 $16,978
$3608 $3608
0.12 0.12
$88 $0
$0 $0
enofovir DF; ZDV, zidovudine.
C  EFV arm of Study CNA30024  5.23% [29].
ed in the tenofovir arm of the ACTG 5142 metabolic substudy [24].se e
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662 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 7 – 6 6 4emphasizing again the importance of utilizing head-to-head data
when available.
For any model, it is important to compare clinically relevant
outcomes of the model with observational studies, to validate how
well the model matches real-world data. Cohort studies have re-
Fig. 2 – Cost-effectiveness acceptability curves. 3TC,
lamivudine; ABC, abacavir; EFV, efavirenz; FTC,
emtricitabine; QALY, quality-adjusted life year; TDF,
Table 5 – Costs, outcomes, and cost-effectiveness of TDF/F
Scenario TD
Base case (discounted lifetime results)*
Costs
Antiretroviral drug costs
Adverse-event costs†
Other medical costs‡
Other medication costs
Total costs
Heath outcomes
Life years
QALYs
Years on first-line therapy
Incremental cost per life year gained
Incremental cost per QALY gained
Results at 5-year time horizon*
Total costs
QALYs
Incremental cost per QALY gained
Percentage remaining on first-line therapy at 5 years
Undiscounted lifetime results
Total costs
Life years
QALYs
Incremental cost per QALY gained
Years on first-line therapy
Percentage of deaths due to AIDS-related causes
Excluding myocardial infarction*
Total costs
QALYs
Incremental cost per QALY gained
3TC, lamivudine; ABC, abacavir; AIDS, acquired immune deficiency
effectiveness ratio; QALY, quality-adjusted life-year; TDF, tenofovir D
* All costs and outcomes discounted at 3% per year.
† Includes costs for anemia, myocardial infarction, HLA-B*5701 scree
‡ Includes costs for disease monitoring, switching therapy lines, treat
anemia, myocardial infarction, HLA-B*5701 screening, and renal m
§ Negative ICER indicates that TDF/FTC  EFV costs less and resultstenofovir DF; ZDV, zidovudine.ported increases in life expectancy over time and have found that
life expectancy varies widely, depending on the year in which
HAART was initiated, age, gender, history of injection drug use,
and baseline viral load and CD4 cell count [4,6,47–48]. A recent
tudy following HIV-infected individuals estimated that life ex-
ectancy for a person aged 35 years has increased from 25.0 years
or individuals initiating therapy from 1996 to 1999, to 37.3 years
or those initiating therapy from 2003 to 2005 [6]. The lower life
xpectancy predicted by our model (26 years) reflects the modeled
opulation (based on participants in Study 934), nearly half of
hich had a baseline CD4 cell count less than 200 cells/L, and
our somewhat conservative assumptions about the duration of
first-line therapy. Notably, our results for estimated life expec-
tancy are within the range (19.2–34.2 years) estimated by other
economic models [8,49,50]. Our model also predicted that for HIV-
infected individuals initiating HAART in the US today (i.e., in 2011),
approximately 21% would die of AIDS-related causes. As expected,
this result is lower than the percentages found in US observational
studies (25%–56%) [2–5] because our model included new, highly
efficacious drugs. These results corroborate recent evidence that
as new HIV-1 treatment regimens are introduced, the risk of death
from AIDS-related causes may continue to decrease and life ex-
pectancy may continue to increase.
One of the strong points of our model is that the comparison of
EFV compared with ABC/3TC + EFV and ZDV/3TC + EFV.
C  EFV ABC/3TC  EFV ZDV/3TC  EFV
82,657 $512,343 $508,948
$2305 $2320 $1480
96,911 $197,057 $201,630
65,453 $65,370 $66,229
47,327 $777,090 $778,287
.22 17.14 17.06
.75 15.68 15.44
.70 6.05 5.84
–$363,683§ –$187,252§
–$440,368§ –$100,860§
61,963 $163,515 $164,540
.116 4.117 4.032
$1,080,351§ –$30,598§
.6% 44.8% 43.0%
00,257 $1,249,208 $1,247,550
.23 26.06 25.88
.00 23.83 23.48
–$295,835§ –$91,827§
.83 7.37 7.11
.6% 21.9% 22.9%
45,575 $774,974 $777,081
.80 15.74 15.48
–$511,665§ –$98,211§
drome; EFV, efavirenz; FTC, emtricitabine; ICER, incremental cost-
V, zidovudine.
, and renal monitoring.
of opportunistic and other infections, and adverse events other than
ring.
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663V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 6 5 7 – 6 6 4collected over a follow-up period of nearly 3 years. The availability
of 144-week data improves the reliability of long-term efficacy es-
timates extrapolated for these two HAART regimens after 144
weeks. In addition, we explicitly modeled adverse events that
were significantly different between the three first-line compara-
tor regimens. Interestingly, our model showed that the cost of
treating adverse events for all three regimens was relatively small
compared with lifetime costs ( 1%). Thus, while safety profiles of
HAART regimens are clinically important, adverse events had a
limited impact on the model’s economic outcomes, mostly due to
relatively low treatment costs compared with antiretroviral drug
costs.
Our analysis has several limitations that should be well under-
stood in interpreting the results. First, the results of this analysis
are restricted to first-line, EFV-based HAART regimens with brand
pricing and full regimen switches upon therapy failure. The anal-
ysis did not consider other NNRTIs (e.g., nevirapine for pregnant
women), third agents from other drug classes, generic drug pric-
ing, or drug substitutions within regimens. This approach was
chosen as a first iteration of the model in order to help inform
clinicians about the cost-effectiveness of first-line, EFV-based reg-
imens. A more complex analysis would be necessary to model and
to evaluate the cost-effectiveness of all possible first-line therapy
options.
Also, recent results of the ACTG 5202 trial reported that TDF/
FTC was significantly more efficacious compared with ABC/3TC
among individuals with high baseline viral loads ( 100,000 cop-
ies/mL) but not among individuals with low baseline viral loads.
Therefore, the results of our analysis, which included better viro-
logic efficacy for TDF/FTC overall, may be most applicable to indi-
viduals who initiate therapy with high viral loads [18–19].
Finally, an indirect comparison between TDF/FTC and ABC/3TC
was necessary in the absence of head-to-head clinical trial data.
However, Study 934 and Study CNA30024 reported remarkably
similar results for ZDV/3TC in combination with EFV. Thus, effi-
cacy data for ABC/3TC from Study CNA30024 required only a small
(upward) adjustment, which was conservative relative to TDF/
FTC. Clinical trials comparing TDF/FTC and ABC/3TC, both with
EFV, in treatment-naïve individuals are currently ongoing [18–21].
esults from the ACTG 5202 trial showed that, among the sub-
roup of participants receiving EFV, more participants receiving
DF/FTC (89.8%) than ABC/3TC (85.3%) remained free of virologic
ailure at 96 weeks [19]. Once full results of the ACTG 5202 trial are
ublished (specifically time to regimen failure), our model’s com-
arison of TDF/FTC with ABC/3TC will be more reliable.
This study revealed that among those initiating HAART with
FV-based regimens, individuals using TDF/FTC may have lower
osts and better short- and long-term health outcomes, compared
ith individuals using either ABC/3TC or ZDV/3TC. More individ-
als with durable viral suppression yielded better clinical out-
omes and cost savings, due to the postponement of more expen-
ive subsequent lines of therapy and lower costs associated with
isease-related resource use.
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